Association between serum uric acid and carotid atherosclerosis in elderly postmenopausal women: A hospital-based

Xiao-Kang Dong1, Dan Luo2, Wen-Jing Chen1

  • 1Department of Cardiovascular, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.

Insights

Elevated serum uric acid (SUA) levels are linked to carotid atherosclerosis (CAS) presence and progression. Hormone replacement therapy (HRT) may offer protective benefits against CAS, warranting further investigation.

Area of Science:

  • Cardiovascular Medicine
  • Vascular Biology
  • Endocrinology

Background:

  • Carotid atherosclerosis (CAS) is a significant risk factor for stroke, contributing to 20-30% of cases.
  • Understanding factors influencing CAS development and progression is crucial for cardiovascular risk management.

Purpose of the Study:

  • To investigate the association between serum uric acid (SUA) levels and the presence and progression of carotid atherosclerosis.
  • To evaluate the potential role of hormone replacement therapy (HRT) in mitigating CAS.

Main Methods:

  • A cohort of 504 patients underwent medical history review, physical examination, carotid ultrasound, and laboratory tests.
  • Logistic and multiple linear regression analyses were used to assess the relationship between SUA and CAS.
  • The impact of HRT on CAS progression was also examined.

Main Results:

  • 81.7% of patients exhibited carotid plaques.
  • Higher SUA levels correlated significantly with an increased probability of carotid plaque presence (OR: 2.01).
  • Increased SUA was associated with greater plaque score and carotid intima-media thickness progression over 2 years.
  • Long-term HRT (≥5 years) was linked to lower SUA, improved lipid profiles, and reduced CAS progression.

Conclusions:

  • Serum uric acid levels are significantly associated with the presence and progression of carotid atherosclerosis.
  • Hormone replacement therapy may potentially prevent CAS development and slow its progression.
  • Further research is needed to confirm the safety and long-term efficacy of HRT for CAS management.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
475
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
85
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
13
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
63
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
163
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
17